#United States #Lexitas #Toledo #NAMSA #Ophthalmic Devices

Strategic Partnership between NAMSA and Lexitas

Recently, a noteworthy collaboration between NAMSA and Lexitas was announced, aiming to enhance the development processes for ophthalmic medical devices. NAMSA, a recognized leader in MedTech contract research, partnered with Lexitas Pharma Services—an expert in ophthalmology clinical research—to provide a comprehensive support mechanism throughout the entire product lifecycle. This partnership promises to offer device sponsors a seamless, unified experience, vastly improving their development journey.

What This Partnership Delivers

The collaborative effort between NAMSA and Lexitas presents an integrated model that contrasts sharply with traditional contractual relationships seen in the industry. In what is described as an 'embedded operating model', Lexitas’ clinical specialists will be directly incorporated into NAMSA’s project management structure. This integration allows for a streamlined process where both organizations share a technology and quality management system, leading to consistently high-quality outcomes.

Services will include end-to-end product lifecycle support that encompasses everything from preclinical studies to pivotal trials, regulatory submissions, and eventual commercialization. Sponsors will gain access to Lexitas' extensive network comprising over 700 investigator sites, reinforced by specialized clinical execution capabilities. Furthermore, Lexitas brings a certified medical monitoring team and a structured BCVA (Best-Corrected Visual Acuity) certification program—crucial for the robustness of ophthalmic studies.

The Strength of Dual Expertise

The partnership combines NAMSA's extensive MedTech background—with experience serving thousands of clients globally—with Lexitas’ unique focus in the specialized field of ophthalmology. This synergy is poised to provide device innovators with device-native clinical research expertise, guaranteeing that they remain informed and compliant throughout FDA requirements while setting a strategic path for both Investigational Device Exemptions (IDE) and trial designs that are robust yet tailored to specific products.

Brian Smith, NAMSA's CEO, stated, "We've listened to what our ophthalmic device sponsors have been asking for—a coordinated solution featuring deep device expertise paired with specialized ophthalmic execution. This partnership enables us to meet that need by providing a cohesive development platform under one contract, significantly simplifying the vendor management process for our sponsors."

On the other side, Jeanne Hecht, CEO of Lexitas, emphasized the integration of their ophthalmic specialists into NAMSA's structure. She noted, "This unprecedented partnership allows for the execution of highly specialized ophthalmic trials with increased confidence and consistency, which is invaluable for our clientele."

Industry Engagement and Future Outlook

Both companies will have a presence at the upcoming ARVO Annual Meeting in Denver, Colorado, showcasing their joint capabilities and how this strategic partnership can enhance development programs for ophthalmic device sponsors. Interested parties are invited to visit the Lexitas booth where they can engage with both teams and learn more about these transformative initiatives.

Conclusion

The NAMSA and Lexitas partnership marks a significant advancement in the landscape of ophthalmic medical device development, offering a robust, streamlined, and expert-driven approach to enhance product innovation while ensuring compliance and efficacy. As they move forward, this collaboration exemplifies how shared expertise can contribute to better patient outcomes and a more efficient development cycle in the ophthalmic space. The combined strength of NAMSA's global reach and Lexitas' specialized focus presents a compelling opportunity for companies looking to bring innovative ophthalmic solutions to market more effectively than ever before.